In 2021, the global real-world evidence solutions market stood at USD 977 million. Recording a CAGR of 13.5% from 2022 to 2028, the worth is projected to reach ~USD 2,371 million by 2028, according to a new report by Gen Consulting Company.

This industry report offers market estimates of the global market, followed by a detailed analysis of the component, therapeutic area, end user, and region. The global market data on real-world evidence solutions can be segmented by component: data sets, services. Real-world evidence solutions market is further segmented by therapeutic area: cardiovascular disease, immunology, neurology, oncology, others. Based on end user, the real-world evidence solutions market is segmented into: healthcare payers, healthcare providers, pharmaceutical & medical device companies, others. On the basis of region, the real-world evidence solutions market also can be divided into: North America, Europe, Asia-Pacific, Rest of the World.

The global real-world evidence solutions market is highly competitive. The competitive landscape of the industry has also been examined along with the profiles of the key players Accenture plc, Clinigen Group Plc, COTA Inc., IBM Corporation, ICON plc, IQVIA Inc., Optum Inc., Oracle Corporation, Parexel International Corporation, PerkinElmer Inc., PPD Inc., Saama Technologies LLC., SAS Institute Inc., Syneos Health Inc., Tempus Labs Inc.

The data-centric report focuses on market trends, status and outlook for segments. With comprehensive market assessment across the major geographies, the report is a valuable asset for the existing players, new entrants and the future investors.


Why buy this report?

  • Get a detailed picture of the Global Real-World Evidence Solutions Market
  • Identify segments/areas to invest in over the forecast period in the Global Real-World Evidence Solutions Market
  • Understand the competitive environment, the market’s leading players
  • The market estimate for ease of analysis across scenarios in Excel format.
  • Strategy consulting and research support for three months.
  • Print authentication provided for the single-user license.